Page 16 - Noble-Virtual-Healthcare-2024

Health Care
Date April 15, 2024 Health Care
52wk High $26.38
52wk Low $4.28 CervoMed Inc. CRVO $25.19
20 Park Plaza
Boston, MA 02116

(USD - in millions) www.cervomed.com
Market Cap 155.4
Enterprise 147.6
Basic Shares Out. 6.17 COMPANY OVERVIEW
Float 2.47
Institutional Holdings 5.63% Detailed Analysis:Channelchek.com
Short Interest 0.02
Avg. 90-Day Volume 0.03 CervoMed Inc. is a clinical-stage company focused on developing
treatments for age-related neurologic disorders. The Company is
currently developing neflamapimod, an investigational, orally
administered small molecule brain penetrant that inhibits p38MAP
EPS Data kinase alpha. Neflamapimod has the potential to treat synaptic
dysfunction, the reversible aspect of the underlying neurodegenerative
2021 2022 2023 processes that causes disease in DLB and certain other major
CQ1 N/A N/A N/A neurological disorders. Neflamapimod is currently being evaluated in a
CQ2 N/A N/A N/A Phase 2b study in patients with DLB.

CQ3 N/A N/A 0.65
CQ4 N/A N/A (0.95)
CY N/A (1.29) (0.82) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 1.30
ROE (ttm) NM
Debt-to-Total Cap. (mrq) N/A
Fiscal Year End 31-Dec
20 Park Plaza Boston MA 02116

Key Executives
CEO: Alam, John
CFO: Elder, William
COO: Cobuzzi, Robert
IR: N/A
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert Leboyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures